@article{6f3e168e31a44213abe440d8410b06fa,
title = "High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura",
abstract = "There is a controversy which short term high dose dexamethasone therapy (HDD) or standard dose prednisolone therapy as the initial treatment leads to long term efficacy in idiopathic thrombocytopenic purpura (ITP) patients. We conducted a multicenter, prospective trial to determine the efficacy and safety of short-term HDD in ITP patients aged 18–80 years with platelet counts of < 20 × 109/l, or < 50 × 109/l and bleeding symptoms. The primary endpoints are the proportion of complete response (CR) plus partial response (R) on day 180 after the completion of the 46-day HDD. Twenty-three patients were enrolled. Test for Helicobacter pylori (H. pylori) was positive for 6 patients and negative for 17 patients. In positive patients, 5 were received successful H. pylori eradication therapy. The proportion of CR + R was 60.9% (14/23) with 90% confidence interval of 41.7–77.8%. For patients with positive H. pylori and successful eradication, the proportion of CR + R was 80.0% (4/5). There was one grade 4 adverse event. Although we have enrolled relatively old, severe ITP patients with a median age of 63 years in this study, the efficacy was comparable to the reported clinical trials with HDD therapy.",
keywords = "High-dose dexamethasone therapy, Idiopathic thrombocytopenic purpura, Open-label, Short-term, Single-arm trial",
author = "Ken Takase and Hirokazu Nagai and Moe Kadono and Takanori Yoshioka and Nobuyuki Yoshio and Yukio Hirabayashi and Takuo Ito and Morio Sawamura and Akihiro Yokoyama and Shinichiro Yoshida and Ikuyo Tsutsumi and Maki Otsuka and Youko Suehiro and Michihiro Hidaka and Isao Yoshida and Hisayuki Yokoyama and Hitoshi Inoue and Hiroatsu Iida and Maki Nakayama and Terutoshi Hishita and Hiromi Iwasaki and Akiko Kada and Saito, {Akiko M.} and Yoshiaki Kuroda",
note = "Funding Information: HN reports grants and personal fees from Janssen Pharmaceutical K.K., Mundipharma K.K., Celgene Corporation, Bayer Yakuhin Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Esai Co., Ltd., Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Gilead Sciences Inc., Zenyaku Kogyo Co., Ltd., AstraZeneca plc., and SymBio Pharmaceuticals Limited, outside the submitted work; grants from Abbvie G.K., Solasia Pharma K.K., HUYA Bioscience International, Otsuka Pharmaceutical Co., Ltd., and IQVIA service Japan K.K., outside the submitted work; personal fees from Roche Ltd., Sanofi K.K., outside the submitted work. HY reports grants from Astellas, outside the submitted work. AK reports personal fees from Bayer Yakuhin, Ltd. for a member of independent data monitoring committee of clinical trials, outside the submitted work. All other authors have nothing to disclose. Funding Information: This study is supported by Grant-in-Aid for Clinical Research from the National Hospital Organization. Publisher Copyright: {\textcopyright} 2020, Japanese Society of Hematology.",
year = "2020",
month = mar,
day = "1",
doi = "10.1007/s12185-019-02808-6",
language = "English",
volume = "111",
pages = "388--395",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",
}